Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeCycle Pharma has presented positive top-line results from a completed Phase II clinical trial for LCP-Tacro in stable kidney transplant patients.
Subscribe to our email newsletter
Data demonstrated that LCP-Tacro has a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Prograf. LCP-Tacro also shows higher bioavailability by more than 40% compared to Prograf with improved pharmacokinetics and reduced variability (peak-to-trough ratio).
Flemming Oernskov, president and CEO of LifeCycle Pharma, said: “The results are a very important milestone for LCP and demonstrate LCP-Tacro’s potential advantages over Prograf. With these positive data we expect to initiate Phase III clinical studies in the second half of 2008. LCP-Tacro will be the first product that we expect to fully develop and commercialize ourselves in selected markets.”